FDA clears IceCure Medical's cryoablation system

By AuntMinnie.com staff writers

April 6, 2021 -- The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to IceCure Medical's ProSense liquid nitrogen-based cryoablation system.

The designation covers the use of the system for treatment of patients with T1 invasive breast cancer and accelerates the FDA's clearance process for this indication, according to the firm. The device is already FDA-cleared for general minimally invasive cryoablation applications, including for kidney, liver, and benign breast tumors, IceCure said.

Copyright © 2021 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking